login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
TCR2 THERAPEUTICS INC (TCRR) Stock News
USA
- NASDAQ:TCRR -
US87808K1060
-
Common Stock
1.48
USD
-0.09 (-5.73%)
Last: 5/31/2023, 8:00:02 PM
1.53
USD
+0.05 (+3.38%)
After Hours:
5/31/2023, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TCRR Latest News, Press Relases and Analysis
All
Press Releases
2 years ago - By: Seeking Alpha
- Mentions:
ADAP
Adaptimmune completes merger with fellow immunology company TCR2 (ADAP)
3 years ago - By: Benzinga
- Mentions:
ESPR
SRTS
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
3 years ago - By: Benzinga
Recap: TCR2 Therapeutics Q1 Earnings
3 years ago - By: TCR2 Therapeutics
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
3 years ago - By: TCR2 Therapeutics
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 years ago - By: Research and Markets
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
3 years ago - By: InvestorPlace
- Mentions:
ADAP
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
3 years ago - By: Kahn Swick & Foti, LLC
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
3 years ago - By: TCR2 Therapeutics
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 years ago - By: TCR2 Therapeutics
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
3 years ago - By: Kahn Swick & Foti, LLC
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
3 years ago - By: Ademi LLP
Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune
3 years ago - By: Halper Sadeh LLC
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
Please enable JavaScript to continue using this application.